NRx Posts Quarterly Loss of $2.175 Million and Prepares to Ship Ketamine in January
Key Facts
NRx Pharmaceuticals reported third-quarter results on November 17, posting a net loss of $2.175 million for the three months ended September 30, compared with $5.890 million in the same period of 2025, according to its filing with the U.S. Securities and Exchange Commission. Basic and diluted loss per share was $0.05, compared with $0.27 a year earlier. The results come as the company prepares to launch its first drug product approved through an ANDA by the U.S. Food and Drug Administration: preservative-free ketamine. Management had received approval for the application on October 29, ahead of the November 10 target under the GDUFA. The company held its third-quarter earnings call on November 17 at 8:00 a.m. Eastern time.
The company said a trained sales team of 17 began sales operations during the week of November 11, and that its network includes relationships with buyers responsible for about 80% of the current U.S. ketamine market. NRx is targeting initial supply agreements and pre-orders in late 2026, with product shipments expected to begin in January 2027. The product has thus entered the commercial launch phase following regulatory approval, while actual sales and shipments remain subsequent milestones on the company’s announced timeline. The company did not say shipments had already begun; it set January as the planned start date. The schedule puts commercial execution at the center of attention after approval cleared the application’s regulatory review hurdle.
The company says injectable ketamine has been on the shortage list since 2018, and that some customers have expressed willingness to enter long-term agreements in exchange for assured supply. The product comes in a blow-fill-seal vial, without a needle or preservative, with a luer-lock tip that connects directly to a sterile syringe. NRx said the ANDA approval allows it to market the product with an initial labeled shelf life of two years. It also said it had completed three commercial-scale validation batches and has manufacturing capacity of about 550,000 units per production cycle. The company cites manufacturing efficiency and its sales structure in forecasting gross and net margins above 50%; these are estimates it announced, not reported realized results.
In its existing business, patient-services revenue rose to $1.159 million in the third quarter from $242,000 in the same period of 2025, according to the filing. But the company used about $19.9 million in cash for operating activities during the nine months ended September 30 and reported a working-capital deficit of $7.0 million. The financial statements said management concluded that substantial doubt existed about the company’s ability to continue as a going concern for at least the 12 months following the issuance of the statements. These indicators put funding and liquidity needs alongside the revenue opportunity tied to the ketamine launch. NRXP shares closed at $2.15 on November 16, according to EL7 data.
In a regulatory track separate from the ANDA approval for the generic product, NRx said it expects to begin submitting an NDA for NRX-100, its intravenous ketamine formulation, during the remainder of 2026. That application concerns a different product and regulatory pathway from the approval for preservative-free ketamine. The FDA label for injectable ketamine lists its use as a general anesthetic and to induce anesthesia before other anesthetic agents; it does not list depression treatment among the approved indications. Therefore, the ANDA approval for the product does not itself constitute approval for use in treating depression. The next specified commercial steps are to target supply agreements and pre-orders in late 2026, followed by the start of shipments in January 2027.